Development of intervention-related quality indicators for renal clinical pharmacists using a modified Delphi approach.
Consensus
Delphi Technique
Female
Humans
Male
Medication Therapy Management
/ organization & administration
Pharmacists
/ standards
Pharmacy Service, Hospital
/ organization & administration
Prevalence
Prospective Studies
Quality Indicators, Health Care
/ standards
Renal Insufficiency, Chronic
/ drug therapy
Surveys and Questionnaires
/ statistics & numerical data
Treatment Outcome
clinical interventions
clinical pharmacy
pharmaceutical care
professional practice
Journal
The International journal of pharmacy practice
ISSN: 2042-7174
Titre abrégé: Int J Pharm Pract
Pays: England
ID NLM: 9204243
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
27
03
2017
accepted:
31
07
2018
pubmed:
14
9
2018
medline:
11
2
2020
entrez:
14
9
2018
Statut:
ppublish
Résumé
To develop a list of renal Quality Indicator Drug therapy problems (QI-DTPs) that serve to advance renal pharmacy practice to improve patient care. Eighteen (18) renal, clinical pharmacists participated in an internet-based three-round modified Delphi survey. Each of the three rounds took approximately 2 weeks to complete. Panellists rated 30-candidate renal QI-DTPs using seven selection criteria and one overall consensus criterion on a nine-point Likert scale. Consensus was reached if 75% or more of panellists assigned a score of 7-9 on the consensus criterion during the third Delphi round. All panellists completed three rounds of Delphi survey. Seventeen-candidate renal QI-DTPs met the consensus definition. A Delphi panel of renal clinical pharmacists successfully identified 17 consensus renal QI-DTPs. Assessment and implementation of these QI-DTPs will serve to advance renal pharmacy practice and improve patient care.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
436-442Informations de copyright
© 2018 Royal Pharmaceutical Society.
Références
Coresh J et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047.
Arora P et al. Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 2013; 185: E417-E423.
Cardone KE et al. Medication-related problems in CKD. Adv Chronic Kidney Dis 2010; 17: 404-412.
Cipolle RJ, Strand LM, Morley PC. Pharmaceutical Care Practice - The Clinician's Guide. New York, NY: The McGraw-Hill Companies, Inc., 2004.
Bruchet N, Loewen P, de Lemos J. Improving the quality of clinical pharmacy services: a process to identify and capture high-value “quality actions”. Can J Hosp Pharm 2011; 64: 42-47.
American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy 2008; 28: 816-817.
Salgado TM et al. Pharmacists’ interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant 2012; 27: 276-292.
Raymond CB, Wazny LD, Sood AR. Standards of clinical practice for renal pharmacists. Can J Hosp Pharm 2013; 66: 369-374.
Manley HJ et al. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005; 46: 669-680.
Levin A et al. Guidelines for the management of chronic kidney disease. CMAJ 2008; 179: 1154-1162.
Goldstein M et al. Multidisciplinary predialysis care and morbidity and mortality of patients on dialysis. Am J Kidney Dis 2004; 44: 706-714.
Grabe DW et al. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997; 121: 459-464.
Pai AB et al. Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: a 2-year randomized, controlled study. Hemodial Int 2009; 13: 72-79.
Wang EH, Co M. Should there be a cap on the number of patients under the care of a clinical pharmacist? The “pro” side. Can J Hosp Pharm 2012; 65: 319-320.
Slavik RS, Lebras M, Gorman SK. Clinical pharmacy activities: we know what to do, but for whom should we do it? (Correspondence). Can J Hosp Pharm 2016; 69: 176-178.
Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol 2011; 12: 35.
Salgado TM et al. Assessing the implementability of clinical pharmacist interventions in patients with chronic kidney disease: an analysis of systematic reviews. Ann Pharmacother 2013; 47: 1498-1506.
Fernandes O et al. Development of clinical pharmacy key performance indicators for hospital pharmacists using a modified Delphi approach. Ann Pharmacother 2015; 49: 656-669.
Grangé S, Hanoy M, Le Roy F. Monitoring of hemodialysis quality-of-care indicators: why is it important? BMC Nephrol 2013; 14: 109.
KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
Campbell SM et al. Research methods used in developing and applying quality indicators in primary care. BMJ 2003; 326: 816-819.
Boulkedid R et al. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One 2011; 6: e20476.
SurveyMonkey Privacy Policy [Internet]. 2015 Jul 8 [cited 2015 Sep 2]. http://www.surveymonkey.com/
Ng J, Harrison J. Key performance indicators for clinical pharmacy services in New Zealand public hospitals: stakeholder perspectives. J Pharm Health Serv Res 2010; 1: 75-84.
Somerville JA. Critical factors affecting the meaningful assessment of student learning outcomes: a Delphi study of the opinions of community college personnel. Oregon State University, Corvallis, OR, 2007 (Unpublished doctoral dissertation).
Minard LV et al. Pharmacists’ perceptions of the barriers and facilitators to the implementation of clinical pharmacy key performance indicators. PLoS One 2016; 11: e0152903.